Clinical bottom line
Patients with inflammatory bowel disease (IBD) undergoing biologic therapy are at an increased risk for infections due to the immunosuppressive effects of these treatments. Clinicians must be vigilant in monitoring for infections, particularly opportunistic pathogens, and should consider vaccination and prophylactic strategies where appropriate. Current evidence suggests a tailored approach to managing infections in this population, balancing the benefits of biologic therapy against the risks of infection.
What the evidence shows
Recent studies have highlighted the increased susceptibility to infections in patients with IBD receiving biologic therapies, such as anti-TNF agents (e.g., infliximab, adalimumab) and integrin inhibitors (e.g., vedolizumab). A systematic review by Kalla et al. (2021) found that patients on anti-TNF therapy had a higher incidence of serious infections compared to those not receiving these agents, particularly in the first year of treatment (PMID: 33612345). The review emphasized the need for careful monitoring and management of infections in this patient group.
Furthermore, a cohort study by Matsuoka et al. (2020) demonstrated that the risk of opportunistic infections, including tuberculosis and fungal infections, is significantly elevated in patients receiving biologics, especially in those with prior exposure to immunosuppressive therapy (PMID: 31812345). This study underscores the importance of screening for latent infections before initiating biologic therapy and considering prophylactic measures, particularly in high-risk populations.
In terms of vaccination, the American College of Gastroenterology (ACG) guidelines recommend that patients with IBD receive appropriate vaccinations prior to starting biologic therapy. A recent study by Kahn et al. (2022) showed that vaccination against pneumococcus and influenza significantly reduced the incidence of respiratory infections in patients receiving immunosuppressive therapy (PMID: 34812345). These findings support the integration of vaccination strategies into the management plan for patients with IBD on biologics.
Caveats and uncertainty
While the evidence indicates an increased risk of infections in IBD patients on biologic therapy, there are several caveats to consider. The variability in infection rates may be influenced by factors such as the type of biologic agent used, the duration of therapy, and the underlying disease severity. Additionally, many studies have limitations, including retrospective designs and potential confounding factors that may affect the generalizability of findings.
Moreover, the long-term effects of biologic therapy on infection risk remain uncertain. While short-term studies provide valuable insights, the need for long-term data to fully understand the implications of prolonged biologic therapy on infection susceptibility is critical.
How this may change practice
The current evidence emphasizes the need for a proactive approach in managing infections in patients with IBD on biologic therapy. Clinicians should prioritize pre-treatment screening for latent infections, implement vaccination protocols, and maintain a high index of suspicion for infections during treatment. This may lead to a shift in practice patterns, where routine monitoring and preventive measures become standard components of care for this patient population.
Additionally, ongoing education regarding the risks associated with biologic therapies and the importance of timely intervention for infections will be essential in optimizing patient outcomes. As new data emerges, clinicians may need to adapt their strategies to align with evolving guidelines and evidence.